In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

A Convergence Problem: Getting the Drug on the Device

Executive Summary

Drug-eluting stents are highly successful medical devices but even their manufacturers don't have adequate solutions for a hidden problem in drug-device combinations; the best way to get the drug on the device. Sarnoff Corp.has a new technology for addressing this complex process. Called electro-static deposition, it brings increased flexibility, reproducibility, accuracy, and uniformity to a manufacturing process which using current methods is costly and inefficient,

You may also be interested in...



Convergent Calling: An Interview with Medtronic's Stephen Oesterle

Historic walls between the medical device and biotech sectors are coming down as medical devices incorporate more biologically-active agents as part of their therapy. That's good news for device companies since device technology in these combination devices is every bit as critical to their clinical success as the biologic.

Medtech Multinationals Up Pace Of Localization Strategies In China

China-specific go-to-market strategies are helping global medtechs access the fast-growing medical device market in China, where localization has become the buzzword for foreign players, writes news and analysis portal Omdia.

Lack Of Interchangeability No Barrier For Amjevita, Says Amgen Executive

While Amgen’s Amjevita (adalimumab-atto) has yet to secure an interchangeability designation, company executives appear confident this will have little impact on their Humira biosimilar’s competitiveness overall.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

IV002497

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel